Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.51 |
| ▸ | EGFR | P00533 | 3/20 | 0.50 |
| ▸ | RET | P07949 | 2/20 | 0.48 |
| ▸ | SYK | P43405 | 2/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | PAK4 | O96013 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16963547 | 0.92 | MKNK1 (0.62) | MKNK1ROCK2EGFRRETROCK1 | |
| SCHEMBL16963619 | 0.91 | MKNK1 (0.48) | MKNK1PDGFRBPDGFRAROCK2EGFR | |
| SCHEMBL16962040 | 0.82 | MKNK1 (0.67) | MKNK1ROCK2EGFRRETSYK | |
| SCHEMBL16963088 | 0.81 | MKNK1 (0.61) | MKNK1ROCK2EGFRRETSYK | |
| SCHEMBL16963343 | 0.80 | MKNK1 (0.65) | MKNK1ROCK2EGFRRETSYK | |
| SCHEMBL4352904 | 0.79 | TTBK1 (0.51) | EGFRABL1HRH4HRH3 | |
| SCHEMBL16963123 | 0.79 | MKNK1 (0.58) | MKNK1EGFRRETJAK2JAK3 | |
| SCHEMBL16371340 | 0.77 | MKNK1 (0.45) | MKNK1ROCK2EGFRROCK1DYRK1A | |
| SCHEMBL16963653 | 0.77 | MKNK1 (0.56) | MKNK1EGFRRET | |
| SCHEMBL16371910 | 0.77 | MKNK1 (0.47) | MKNK1ROCK2SYKROCK1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150218173-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-06 | — | — | US | disclosed |
| US-20150218173-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-06 | — | — | US | disclosed |
| EP-2900670-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2015-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218173-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | CCND2, ARG2, ARG1 | MKNK1 2957/4885PDGFRB 154/4885PDGFRA 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.